Cdc25C在人脑膜瘤组织中的表达及其临床意义

Expression and clinical meanings of Cdc25C in human meningioma tissues

目的探讨人脑膜瘤组织细胞分裂周期蛋白25同源蛋白C(Cdc25C)的表达及其临床意义。方法选取手术切除并经病理证实的36例人脑膜瘤组织和6例人正常脑组织,提取相应组织的总RNA后,分别以RT-PCR和qPCR技术检测Cdc25C cDNA和mRNA,并结合病人的临床资料进行统计分析。结果 Cdc25C在人脑膜瘤组织中的阳性率为66.67%,明显高于其在正常人脑组织中的阳性率16.67%(P<0.05);Cdc25C mRNA在人脑膜瘤组织中的表达量约为其在人正常脑组织中的3.3倍(P<0.05)。Cdc25C在脑膜瘤组织中的阳性率和阳性表达水平均与病人的年龄、性别、肿瘤大小、病理类型及WHO病理分级等临床病理特征无关(P>0.05)。结论 Cdc25C过表达可能与脑膜瘤的发生相关。

Objective To study the relationship between Cdc25 C in meningioma tissues and pathogenesis of meningiomas.Methods The levels of Cdc25 C DNA and mRNA expressions were detected by RT-PCR and qPCR respectively in the 36 cases of human meningioma tissues and 6 cases of normal human brain tissues. Results The positive rate of Cdc25 C(66.67%, 24/36) was significantly higher in the meningiomas tissues than that in the normal brain tissues(P<0.05). The level of Cdc25 C mRNA expression was significantly higher in the meningioma tissues than that in the normal human brain tissues(P<0.05). The positive rate and expression level of Cdc25 C in the meningioma tissues were not significantly related with the patient’s age and gender, and tumor size, pathologic type and the WHO pathological grade(P>0.05). Conclusion It is suggested that the overexpression of Cdc25 C may be associated with the pathologenesis of meningioma.